Anna Squadrilli

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC

Melissa Bersanelli, Roberta Minari, Paola Bordi et al. · Journal of Thoracic Oncology · 2016 · 166 citations · Full text

Medicine, Medicinal Chemistry, Oncology +15

Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

Giulia Mazzaschi, Roberta Minari, Alessandra Zecca et al. · Lung Cancer · 2020 · 117 citations

Life Sciences, Immunology, Oncology +17

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Silvia La Monica, Roberta Minari, Daniele Cretella et al. · Journal of Experimental & Clinical Cancer Research · 2019 · 70 citations · Full text

Medicine, Oncology, Pharmacology +15

From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC

Paola Bordi, Marzia Del Re, Roberta Minari et al. · Lung Cancer · 2019 · 53 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

Filippo Gustavo Dall’Olio, Francesca Abbati, Francesco Facchinetti et al. · Therapeutic Advances in Medical Oncology · 2020 · 47 citations · Full text

Medicine, Oncology, Pharmacotherapy +17